Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Universal influenza virus vaccines and therapeutic antibodies

Identifieur interne : 000257 ( Main/Exploration ); précédent : 000256; suivant : 000258

Universal influenza virus vaccines and therapeutic antibodies

Auteurs : Raffael Nachbagauer [États-Unis] ; Florian Krammer [États-Unis]

Source :

RBID : PMC:5389886

Abstract

Background

Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.

Aims

To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.

Sources

PubMed and clinicaltrials.gov were used as sources for this review.

Content

Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.

Implications

Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.


Url:
DOI: 10.1016/j.cmi.2017.02.009
PubMed: 28216325
PubMed Central: 5389886


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Universal influenza virus vaccines and therapeutic antibodies</title>
<author>
<name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name>
<affiliation wicri:level="2">
<nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name>
<affiliation wicri:level="2">
<nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">28216325</idno>
<idno type="pmc">5389886</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389886</idno>
<idno type="RBID">PMC:5389886</idno>
<idno type="doi">10.1016/j.cmi.2017.02.009</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000887</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000887</idno>
<idno type="wicri:Area/Pmc/Curation">000887</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000887</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000182</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000182</idno>
<idno type="wicri:Area/Ncbi/Merge">000D51</idno>
<idno type="wicri:Area/Ncbi/Curation">000D51</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D51</idno>
<idno type="wicri:doubleKey">1198-743X:2017:Nachbagauer R:universal:influenza:virus</idno>
<idno type="wicri:Area/Main/Merge">000257</idno>
<idno type="wicri:Area/Main/Curation">000257</idno>
<idno type="wicri:Area/Main/Exploration">000257</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Universal influenza virus vaccines and therapeutic antibodies</title>
<author>
<name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name>
<affiliation wicri:level="2">
<nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name>
<affiliation wicri:level="2">
<nlm:aff id="A1">Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title>
<idno type="ISSN">1198-743X</idno>
<idno type="eISSN">1469-0691</idno>
<imprint>
<date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec id="S1">
<title>Background</title>
<p id="P1">Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches which lead to sharp drops in vaccine effectiveness and long response times in case of novel pandemic viruses.</p>
</sec>
<sec id="S2">
<title>Aims</title>
<p id="P2">To provide an overview of universal influenza virus vaccines and therapeutic antibodies in pre-clinical and clinical development.</p>
</sec>
<sec id="S3">
<title>Sources</title>
<p id="P3">PubMed and
<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>
were used as sources for this review.</p>
</sec>
<sec id="S4">
<title>Content</title>
<p id="P4">Universal influenza virus vaccines that target conserved regions of the influenza virus including the hemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late pre-clinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance our preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection.</p>
</sec>
<sec id="S5">
<title>Implications</title>
<p id="P5">Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections.</p>
</sec>
</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>État de New York</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Nachbagauer, Raffael" sort="Nachbagauer, Raffael" uniqKey="Nachbagauer R" first="Raffael" last="Nachbagauer">Raffael Nachbagauer</name>
</region>
<name sortKey="Krammer, Florian" sort="Krammer, Florian" uniqKey="Krammer F" first="Florian" last="Krammer">Florian Krammer</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000257 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000257 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:5389886
   |texte=   Universal influenza virus vaccines and therapeutic antibodies
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28216325" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021